Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CEL 1000

Drug Profile

CEL 1000

Alternative Names: CEL-1000; CEL-1000 peptide; derG; DGQEEKAGVVSTGLIGGG

Latest Information Update: 18 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; National Institute of Allergy and Infectious Diseases; Naval Medical Research Center; United States Army Medical Research Institute of Infectious Diseases; University of Arkansas System; University of Nebraska Medical Center
  • Class Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Eastern equine encephalomyelitis; Hepatitis B; Herpes simplex virus infections; Influenza A virus H5N1 subtype; Malaria; Severe acute respiratory syndrome; Smallpox; Vaccinia; Venezuelan equine encephalomyelitis; West Nile virus infections; Western equine encephalitis virus infections
  • Discontinued Chlamydial infections

Most Recent Events

  • 08 Jun 2018 CEL-SCI has patent protection for LEAPS technology in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top